EUVIMEDEUVIMED entdecken
Crossref

Molecular characterization and prognosis of mutant TP53 acute myeloid leukemia and myelodysplastic syndrome with excess blasts

Kai Shen iD, De-Yuan Hu iD, Zhi-Bo Zhang, Yu-Sha Guo, Feng-Hong Zhang, Su-Ning Chen

International Journal of Laboratory Hematology · 2023

DOI: 10.1111/ijlh.14030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Laboratory Hematology, 2023. Verfasst von Kai Shen und 5 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Soo…. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: the Innovation Capability Development Project of Jiangsu Province, the National Key R&D Program of China, the Translational Research Grant of NCRCH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Myeloid tumors typically harbor TP53 mutations, which are linked to a dismal prognosis. There are fewer studies on whether TP53‐mutated acute myeloid leukemia (AML) and myelodysplastic syndrome with excess blasts (MDS‐EB) differ in molecular characteristics and should be considered as separate entities.

Methods

Between January 2016 and December 2021, a retrospective analysis was done on a total of 73 newly diagnosed AML patients and 61 MDS‐EB patients from the first affiliated hospital of Soochow University. We described a survival profile and a thorough characterization of newly found TP53‐mutant AML and MDS‐EB and investigated the relationship between these characteristics and overall survival (OS).

Results

38 (31.1%) were mono‐allelic, and 84 (68.9%) were bi‐allelic. There is no significant difference between TP53‐mutated AML and MDS‐EB (median OS 12.9 verse 14.4 months; p = .558). Better overall survival was linked to mono‐allelic TP53 than bi‐allelic TP53(HR = 3.030, CI:1.714–5.354, p < .001). However, the number of TP53 mutations and comutations were not significantly associated with OS. TP53 variant allele frequency cutoff of 50% is significant correlation with OS (HR: 2.177, 95% CI: 1.142–4.148; p = .0063).

Conclusion

Our data revealed that allele status and allogeneic hematopoietic stem cell transplant independently affect the prognostic of AML and MDS‐EB patients, with a concordance of molecular features and survival between these two disease entities. Our analysis favors considering TP53‐mutated AML/MDS‐EB as a distinct disorder.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesLeukemia, Myeloid, AcuteHumansRetrospective StudiesPrognosisMutationTumor Suppressor Protein p53

Stichwörter der Autor:innen

TP53 mutationacute myeloid leukemiamolecular characterizationmyelodysplastic syndrome with excess blastsprognosis

Substanzen

TP53 protein, humanTumor Suppressor Protein p53

Autor:innen und Institutionen

  • National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Soochow University, Suzhou, People's Republic of China.
  • Institute of Blood and Marrow Transplantation, Soochow University, Suzhou, People's Republic of China.

ORCID-Profile: Kai Shen, De-Yuan Hu

Förderung

  • the Innovation Capability Development Project of Jiangsu Province
  • the National Key R&D Program of China
  • the Translational Research Grant of NCRCH

Zitieren

APA

Shen, K., Hu, D. Y., Zhang, Z. B., Guo, Y. S., Zhang, F. H., & Chen, S. N. (2023). Molecular characterization and prognosis of mutant TP53 acute myeloid leukemia and myelodysplastic syndrome with excess blasts. International Journal of Laboratory Hematology. https://doi.org/10.1111/ijlh.14030

Vancouver

Shen K, Hu DY, Zhang ZB, Guo YS, Zhang FH, Chen SN. Molecular characterization and prognosis of mutant TP53 acute myeloid leukemia and myelodysplastic syndrome with excess blasts. International Journal of Laboratory Hematology. 2023. doi:10.1111/ijlh.14030

BibTeX
@article{Shen2023,
  author = {Shen, Kai and Hu, De-Yuan and Zhang, Zhi-Bo and Guo, Yu-Sha and Zhang, Feng-Hong and Chen, Su-Ning},
  title = {Molecular characterization and prognosis of mutant TP53 acute myeloid leukemia and myelodysplastic syndrome with excess blasts},
  journal = {International Journal of Laboratory Hematology},
  year = {2023},
  doi = {10.1111/ijlh.14030}
}
Kostenlos starten →